DK1495769T3 - Mannose-6-phosphat-receptormedieret gentransfer til muskelceller - Google Patents

Mannose-6-phosphat-receptormedieret gentransfer til muskelceller

Info

Publication number
DK1495769T3
DK1495769T3 DK03077205T DK03077205T DK1495769T3 DK 1495769 T3 DK1495769 T3 DK 1495769T3 DK 03077205 T DK03077205 T DK 03077205T DK 03077205 T DK03077205 T DK 03077205T DK 1495769 T3 DK1495769 T3 DK 1495769T3
Authority
DK
Denmark
Prior art keywords
mannose
muscle cells
phosphate receptor
gene transfer
mediated gene
Prior art date
Application number
DK03077205T
Other languages
English (en)
Inventor
Gerard Johannes Platenburg
Original Assignee
Lbr Medbiotech B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lbr Medbiotech B V filed Critical Lbr Medbiotech B V
Application granted granted Critical
Publication of DK1495769T3 publication Critical patent/DK1495769T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK03077205T 2003-07-11 2003-07-11 Mannose-6-phosphat-receptormedieret gentransfer til muskelceller DK1495769T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03077205A EP1495769B1 (en) 2003-07-11 2003-07-11 Mannose-6-phosphate receptor mediated gene transfer into muscle cells

Publications (1)

Publication Number Publication Date
DK1495769T3 true DK1495769T3 (da) 2008-06-23

Family

ID=33442814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03077205T DK1495769T3 (da) 2003-07-11 2003-07-11 Mannose-6-phosphat-receptormedieret gentransfer til muskelceller

Country Status (5)

Country Link
EP (1) EP1495769B1 (da)
AT (1) ATE387217T1 (da)
DE (1) DE60319354T2 (da)
DK (1) DK1495769T3 (da)
ES (1) ES2302898T3 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2361325T3 (es) 2004-06-28 2011-06-16 The University Of Western Australia Oligonucleótidos antisentido para inducir la omisión de exón y métodos de uso de los mismos.
GB0524987D0 (en) 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2008018795A1 (en) 2006-08-11 2008-02-14 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
DK2167136T3 (da) 2007-07-12 2016-07-25 Biomarin Tech Bv Molekyler til målretning af forbindelser på forskellige udvalgte organer eller væv
EP2167135A2 (en) 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4174178A1 (en) 2008-10-24 2023-05-03 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
JP2012524540A (ja) 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー.ブイ. Dmdを処置するためのイノシンを含むオリゴヌクレオチド
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース6−リン酸受容体を標的とする化合物
EP3431603A1 (en) 2009-11-12 2019-01-23 The University Of Western Australia Antisense molecules and methods for treating pathologies
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
EP2806900B1 (en) 2012-01-27 2021-12-15 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
KR102112892B1 (ko) 2012-11-15 2020-05-19 로슈 이노베이션 센터 코펜하겐 에이/에스 올리고뉴클레오티드 콘쥬게이트
MY177989A (en) 2013-01-30 2020-09-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
IL280443B (en) 2013-03-14 2022-07-01 Sarepta Therapeutics Inc Preparations that skip axon for the treatment of muscular dystrophy
EA201591792A1 (ru) 2013-03-15 2016-02-29 Сарепта Терапьютикс, Инк. Улучшенные композиции для лечения мышечной дистрофии
ES2770667T3 (es) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TWI794662B (zh) 2016-03-14 2023-03-01 瑞士商赫孚孟拉羅股份公司 用於降低pd-l1表現之寡核苷酸
CN113474633A (zh) 2019-02-26 2021-10-01 罗氏创新中心哥本哈根有限公司 寡核苷酸配制方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups

Also Published As

Publication number Publication date
ES2302898T3 (es) 2008-08-01
EP1495769A1 (en) 2005-01-12
DE60319354T2 (de) 2009-03-26
EP1495769B1 (en) 2008-02-27
ATE387217T1 (de) 2008-03-15
DE60319354D1 (de) 2008-04-10

Similar Documents

Publication Publication Date Title
DK1495769T3 (da) Mannose-6-phosphat-receptormedieret gentransfer til muskelceller
EP1191098A3 (en) Pharmaceutical composition for treatment of duchenne muscular dystrophy
EP2487258A3 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2206781A3 (en) Antisense oligonucleotides for inducing exon skipping and methods of use thereof
IS2957B (is) Fullmanngerð mótefni gegn 4-1BB (CD137) í mönnum
IL164637A0 (en) Vaginal care compositions containing viable microorganisms
EP2596803A3 (en) Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2007125429A3 (en) Method for the synthesis of triazole- containing oligonucleotide derivatives
NZ600183A (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
EP1608781A4 (en) NON-INVASIVE PRENATAL GENE DIAGNOSIS USING TRANSCERVICAL CELLS
EP1671998A3 (en) Process to form compound with indolocarbazole moieties
WO2007072061A3 (en) Crystalline pyrimidine nucleoside derivatives suspensions in capsules
WO2003006070A3 (en) Improved chelator conjugates
IL179303A0 (en) Preparation of macromolecular conjugates by four-component condensation reaction
EP1781082A4 (en) BIOLOGICAL TRANSFER SYSTEM FOR EUKARYON CELLS
EP1592813A4 (en) METHOD FOR TESTING GROUP TRANSFER REACTIONS
ZA200805703B (en) Preparation of pharmaceutical salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid
IL174804A0 (en) Retroviral vectors for delivery of interfering rna
Lundin et al. Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored “Bioplex” formation
Hu et al. Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy) phenyl] pyrrolocytosine
WO2005072053A9 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
EP2474328A3 (en) Mechanism-based targeted pancreatic beta cell imaging and therapy
EP1129725A3 (en) Oligonucleotide conjugates
Sando et al. Facile preparation of DNA-tagged carbohydrates
JP2003508618A5 (da)